{"organizations": [], "uuid": "fb7fb154358923e84c77fdc30b0f371b5603cfab", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180215.html", "section_title": "Archive News &amp; Video for Thursday, 15 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-astrazeneca-says-selumetinib-in-nf/brief-astrazeneca-says-selumetinib-in-nf1-gets-fda-orphan-drug-status-idUSFWN1Q50DX", "country": "US", "domain_rank": 408, "title": "BRIEF-Astrazeneca Says ‍Selumetinib In Nf1 Gets FDA Orphan Drug Status​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.157, "site_type": "news", "published": "2018-02-15T15:29:00.000+02:00", "replies_count": 0, "uuid": "fb7fb154358923e84c77fdc30b0f371b5603cfab"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-astrazeneca-says-selumetinib-in-nf/brief-astrazeneca-says-selumetinib-in-nf1-gets-fda-orphan-drug-status-idUSFWN1Q50DX", "ord_in_thread": 0, "title": "BRIEF-Astrazeneca Says ‍Selumetinib In Nf1 Gets FDA Orphan Drug Status​", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}, {"name": "selumetinib", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "astrazeneca plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 15 (Reuters) - Astrazeneca Plc:\n* ‍SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS​ * US FDA GRANTED ORPHAN DRUG DESIGNATION (ODD) FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1)​\n* ‍SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS​ * ‍PHASE II TRIAL RESULTS ARE EXPECTED LATER IN 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T15:29:00.000+02:00", "crawled": "2018-02-16T16:38:56.005+02:00", "highlightTitle": ""}